Cognition Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing zervimesine for neurodegenerative diseases. Its Form 8-K reports cover financial results, Regulation FD presentations, clinical-development announcements, FDA meeting disclosures, and material agreements, including an at-the-market common-stock sales arrangement.
Proxy materials disclose annual meeting and stockholder voting matters, while registration and current-report disclosures identify the company’s Delaware corporate status, emerging growth company reporting status, and Nasdaq-listed common stock. The filings also provide formal records of capital-structure activity, governance processes, and risk areas associated with clinical research, regulatory review, grant funding, and the financing needs of a development-stage biotechnology company.
Cognition Therapeutics, Inc. (CGTX) filed a Form 8-K to disclose the voting results of its 18 June 2025 virtual Annual Meeting of Stockholders.
- Director elections: Stockholders elected Class I directors Peggy Wallace (8,566,458 FOR; 2,590,981 WITHHELD) and Ellen B. Richstone (8,686,877 FOR; 2,470,562 WITHHELD). Each will serve until the 2028 annual meeting, subject to the usual contingencies. There were 22,760,336 broker non-votes for each nominee.
- Auditor ratification: Ernst & Young LLP was confirmed as the Company’s independent registered public accounting firm for fiscal 2025 with 33,457,921 FOR, 327,242 AGAINST and 132,612 ABSTAIN votes; no broker non-votes were recorded.
No additional proposals or material business developments were reported.